Cellular Origins, Cell and Gene Therapy Catapult and Resolution Therapeutics have formed a consortium to deliver a fully automated robotics CGT manufacturing platform.
The consortium has been awarded a cross-industry Smart Grant of GBP 1 million ($1.3 million) from Innovate UK, UK's national innovation agency.
The 20-month project aims to use novel technologies to deliver a globally unique, hyper-efficient, fully automated, scalable cell therapy manufacturing platform. The consortium partners will combine their respective expertise in robotic and digital technologies, manufacturing processes, operations and facilities management, therapy development, novel product processes and patient delivery.
The project will deliver full integration of the hardware and software of Cellular Origins’ CGT robotic manufacturing platform, Constellation, at the CGT Catapult’s digital and automation testbeds in the Stevenage Manufacturing Innovation Centre, UK. The testbeds serve as GMP-mirroring sandbox environments for de-risked and accelerated testing and adoption of next-gen technologies. CGT Catapult will commission the platform within the real-world manufacturing environment of its testbeds to support the national and international roll-out of Constellation.
Resolution Therapeutics — a University of Edinburgh spinout developing new type of cell therapy known as regenerative macrophage therapy in inflammatory and fibrotic diseases — will inform the development direction and viability to ensure the adaptability of the platform for novel cell therapies.
Cellular Origins has already completed pre-activity for the project by installing the first Constellation system at the testbeds. The intention is for full market supply and application of the automated robotics manufacturing platform for CGT developers, integrating known and proven instrumentation from trusted third-party suppliers with minimum process change, within Cellular Origins’ workstations and factory installations.
Providing additional support to the project are ScaleReady with its G-Rex bioreactor platform, and Autolomous with its AutoloMATE eBMR solution.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!